Evaluation of CYT-108, a Recombinant Protease Inhibitor, for Treatment of Mild to Moderate Primary Osteoarthritis of the Knee
Phase 1
Not yet recruiting
- Conditions
- OsteoarthritisOsteoarthritis, Knee
- Interventions
- Other: Phosphate Buffered Saline (PBS)Biological: CYT-108, a recombinant protease inhibitor
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Cytonics Corporation
- Target Recruit Count
- 22
- Registration Number
- NCT06263270
- Locations
- 🇦🇺
Emeritus Research, Camberwell, Victoria, Australia
Safety and Efficacy Study of APIC-PRP in Non-healing Diabetic Foot Ulcers
Not Applicable
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Other: Placebo, Saline plus standard of careDevice: APIC-PRP
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Cytonics Corporation
- Target Recruit Count
- 274
- Registration Number
- NCT02209662
APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee
Phase 1
- Conditions
- OsteoarthritisPain
- Interventions
- Device: APIC-CF, 2 ccDevice: APIC-CF, 4 cc
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Cytonics Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT02210468
- Locations
- 🇺🇸
IRC Clinical, Townsend, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath